Business Context and Reporting Period
Company: Organogenesis Holdings Inc. (ORGO)
Reporting Period: Quarter ended March 31, 2026 (Q1 2026)
Business Overview: A regenerative medicine company focused on advanced wound care and surgical/sports medicine markets. The company operates as a single segment and sells products to hospitals, wound care centers, and physician offices.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $37.2 million | $86.7 million |
| Net Product Revenue | $36.3 million | $86.7 million |
| Net Loss | $(53.2) million | $(18.8) million |
| Net Loss Attributable to Common Stockholders | $(56.2) million | $(21.6) million |
| Diluted EPS | $(0.44) | $(0.17) |
| Operating Cash Flow | $21.1 million | $(19.9) million |
| Cash and Cash Equivalents | $91.4 million | $110.5 million (end of period Q1 2025) |
| Working Capital | $190.1 million | N/A |
| Debt | $0 outstanding borrowings | $0 outstanding borrowings |
Liquidity: The company has $75.0 million available under its Revolving Facility, expiring August 6, 2026. Management expects current cash and working capital to fund operations for at least 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Net product revenue decreased 58% year-over-year to $36.3 million. This was driven primarily by a 63% drop in Advanced Wound Care revenue ($29.5M vs $79.9M), attributed to market disruption and clinician confusion following CMS policy changes regarding Local Coverage Determinations (LCDs) and discarded product rules.
- Restructuring Charges: The company incurred a total charge of $8.8 million in Q1 2026 related to a restructuring plan, including closing the St. Petersburg, Florida facility and reducing headcount by 88 employees (approx. 10%). This included $2.8M in severance, $4.9M in intangible asset write-downs, and $1.0M in inventory write-downs.
- Inventory Write-downs: Cost of goods sold increased 9% due to $3.3 million in inventory write-downs for excess and obsolete inventory resulting from regulatory changes and facility closures.
- Operating Cash Flow Improvement: Despite a larger net loss, operating cash flow turned positive ($21.1M) compared to a use of cash ($19.9M) in the prior year, largely due to a $104.5 million decrease in accounts receivable.
Outlook, Risks, and Management Commentary
- Regulatory Environment: CMS finalized 2026 Medicare reimbursement rules (PFS and OPPS) effective January 1, 2026, which may materially and adversely impact product utilization and revenue. The WISeR Model testing began in six states, potentially restricting access.
- Product Pipeline:
- ReNu: Rolling Biologics License Application (BLA) submitted to the FDA in December 2025 and completed on April 24, 2026.
- Dermagraft: Manufacturing and sales remain suspended. Transition to the new Smithfield, Rhode Island facility is expected to begin in 2027, with sales resumption planned for the end of 2027.
- Facility Expansion: The company is building out a new biomanufacturing facility in Smithfield, RI, with Phase 1 completed in December 2025 and Phase 2 expected in 2027.
- Risks: Continued revenue decline due to reimbursement changes, potential delays in the Smithfield facility build-out, and the need for additional financing if cash burn exceeds projections.
Investor Verification Checklist
- Cash Runway: Verify if the $91.4M cash balance and $75M credit facility are sufficient given the current revenue trajectory and restructuring costs.
- Reimbursement Impact: Assess the long-term financial impact of the 2026 CMS PFS/OPPS rules and the WISeR Model on the Advanced Wound Care portfolio.
- Dermagraft Timeline: Monitor progress on the Smithfield facility build-out and FDA approval, as delays could further impact revenue recovery.
- Restructuring Execution: Track the realization of cost savings from the St. Petersburg facility closure and workforce reduction.
- Accounts Receivable: Investigate the $104.5M reduction in accounts receivable to ensure it reflects collections rather than aggressive write-offs or credit loss adjustments.